Real-life safety profile of biosimilar adalimumab in patients with inflammatory arthritic conditions

V. Kaushik, S. Apparao

Arthritis & Rheumatism Centre, Chennai, Chennai, India

Published in: EULAR/Annals of the Rheumatic Diseases, June/2017/76(2)
Objective & Methods

- We share our experience on the real-life safety profile of biosimilar adalimumab following its clinical use in patients with RA and AS.

- Patients with RA or AS treated with biosimilar adalimumab in our outpatient clinic at Arthritis and Rheumatism Centre during the period of 17 Dec 2014 to 30 Mar 2016 were considered for this analysis. The patients were prescribed biosimilar adalimumab 40 mg subcutaneously every fortnight for a minimum of 6 months. The patients were followed up till the end of the treatment, and any safety signals or adverse events reported were collected and analyzed.
**Result**

- A total of 200 patients - 119 patients with AS and 81 patients with RA - who received biosimilar adalimumab therapy for a period of 6 months were included. About 90% (181 out of 200 patients) received concomitant therapy with methotrexate.

- Biosimilar adalimumab therapy was well tolerated by all patients, with no serious adverse events. Adverse events were noted in only 2 patients - one patient had developed pulmonary tuberculosis in the 4th month of treatment, biosimilar adalimumab was discontinued and AKT treatment was started; while another patient experienced rise in transaminases for which, the dose of methotrexate was reduced. Overall assessment of tolerability as “Excellent” was 65.5% by the treating physician and 82% by patients.
Conclusion

• To the best of our knowledge, this is the first report on “real-life” use of biosimilar adalimumab in such a large number of patients. The analysis reveals a safety and tolerability profile of biosimilar adalimumab comparable to that of the innovator product.
COMPOSITION: Exemptia™ (Adalimumab) 40 mg /0.8 mL single use pre filled syringe and 20 mg /0.4 mL single use pre filled syringe

DESCRIPTION: EXEMPTIATM (Adalimumab) is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF-α). EXEMPTIATM is supplied as a sterile, preservative-free solution of Adalimumab for subcutaneous administration. The solution of EXEMPTIATM is clear and colorless.

MECHANISM OF ACTION: Adalimumab binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF-alpha receptors. Adalimumab also lyses surface TNF expressing cells in vitro in the presence of complement. Elevated levels of TNF-α is found in the synovial fluid of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis patients and play an important role in both the pathologic inflammation and the joint destruction that are hallmarks of these diseases.

INDICATIONS & DOSAGE: Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis: The recommended dose of EXEMPTIATM for adult patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) is 40 mg subcutaneously administered every other week. Methotrexate (MTX), other non-biologic DMARDS, glucocorticoids, nonsteroidal anti-inflammatory drugs (NSAIDs), and/or analgesics may be continued during treatment with EXEMPTIATM. Juvenile Idiopathic Arthritis: Exemptia™ dosing in JIA is based on weight; for 10 kg (22 lbs) to < 15 kg (33 lbs): 10 mg s.c. every other week. For 15 kg (33 lbs) to < 30 kg (66 lbs): 20 mg s.c. every other week and for ≥ 30 kg (66 lbs): 40 mg s.c. every other week. Plaque Psoriasis or Non-Infectious Uveitis: Initial dose of 80 mg, followed by 40 mg every other week starting from week one after initial dose. Hidradenitis Suppurativa: 160 mg (Day 1) (four 40 mg injections in one day or two 40 mg injections per day for two consecutive days), followed by 80 mg two weeks later (Day 15). Two weeks later (Day 29) begin a maintenance dose of 40 mg every week. Adult Crohn’s Disease and Ulcerative Colitis: Initial dose (Day 1): 160 mg s.c. (four 40 mg injections in one day or two 40 mg injections per day for two consecutive days). Second dose two weeks later (Day 15): 80 mg. Two weeks later (Day 29): Begin a maintenance dose of 40 mg s.c. every other week. Pediatric Crohn’s Disease: For weight 17 kg (37 lbs) to < 40 kg (88 lbs): Initial dose (Day 1): 80 mg s.c. (two 40 mg injections in one day). Second dose two weeks later (Day 15): 40 mg s.c.. Two weeks later (Day 29): Begin a maintenance dose of 20 mg s.c. every other week. For ≥ 40 kg (88 lbs): Initial dose (Day 1): 160 mg s.c. (four 40 mg injections in one day or two 40 mg injections per day for two consecutive days). Second dose two weeks later (Day 15): 80 mg s.c. (two 40 mg injections in one day). Two weeks later (Day 29): Begin a maintenance dose of 40 mg s.c. every other week.

CONTRAINDICATIONS: Hypersensitivity to the active substance or to any of the excipients, Moderate to severe heart failure, Active tuberculosis or other severe infections such as sepsis and opportunistic infections.

SPECIAL WARNINGS AND PRECAUTIONS: Serious and fungal infections: Do not start EXEMPTIATM during an active infection. If an infection develops, monitor carefully, and stop EXEMPTIATM if infection becomes serious. Anaphylaxis or serious allergic reactions may occur. Hepatitis B virus reactivation: Monitor HBV carriers during and several months after therapy. If reactivation occurs, stop EXEMPTIATM and begin antiviral therapy.

Demelinating disease: Exacerbation or new onset, may occur. Heart failure: Worsening or new onset, may occur. Lupus-like syndrome: Stop EXEMPTIATM if syndrome develops.

USE IN PREGNANCY AND LACTATION: Pregnancy Category B: Adequate and well controlled studies with EXEMPTIATM have not been conducted in pregnant women. Adalimumab is an IgG1 monoclonal antibody and IgG1 is actively transferred across the placenta during the third trimester of pregnancy. Lactation: No data is available on the absorption of adalimumab from breast milk in newborn or preterm infants. Caution should be exercised when EXEMPTIATM is administered to a nursing woman.

DRUG INTERACTION: Biological Products- Concomitant administration of EXEMPTIATM with other biologic DMARDS (e.g., Anakinra and Abatacept) or other TNF blockers is not recommended. Live Vaccines- Avoid the use of live vaccines with EXEMPTIA™ during an active infection. If an infection develops, monitor carefully, and stop EXEMPTIA™ if infection becomes serious. Anaphylaxis or serious allergic reactions may occur.

Biological products should be administered at least 24 hours after or 24 hours before initiating or discontinuing EXEMPTIATM, respectively.

UNDESIRED EFFECTS: The most serious adverse reactions include the following:

- Serious Infections: Tuberculosis and Opportunistic Infections
- Malignancies: The clinical experience has reported Upper Respiratory Tract Infection (URT), Increased creatinine phosphokinase, Headache, Rash, Sinusitis, Nausea, Urinary Tract Infection (UTI), Abdominal pain, Flu-like syndrome, Hyperlipidemia, Back pain, Hypercholesterolemia, Hematuria, Hypertension, Increased alkaline phosphatase as common side effects.

STORAGE CONDITION: Store between + 2 °C and + 8 °C, in the carton to protect from light. Do not freeze Exemptia™. Do not use Exemptia™ if frozen, even if it has been thawed. Keep out of reach of children.

PRESENTATION: a) Injection: 40 mg/0.8 mL in a single-use prefilled syringe b) Injection: 20 mg/0.4 mL in a single-use prefilled syringe.
Please consult full Prescribing Information before prescribing.

Zydus Cadila does not recommend the use of any product in any different manner than as described in the prescribing information.

Further information is available on request from:

Cadila Healthcare Limited
Zydus Corporate Park
Nr. Vaishno Devi Circle,
SG Highway,
Ahmedabad – 382 481
Gujarat, India.
PHONE: +91-79-71800000
Thank you